Overweight and obesity are a growing problem in Mexico. Danish pharmaceutical company Novo Nordisk announced a millionaire investment in clinical research and drugs for the treatment of diabetes in the country. Meanwhile, UNAM, through the Faculty of Higher Studies (FES) reported the development of a tortilla designed to combat malnutrition, obesity and diabetes.
Internationally, prescription drugs for cholesterol treatment top the list of top-selling medicines and Sanofi, the French pharmaceutical company, positioned itself as the biggest Clexane manufacturer. Also, the Health Science division of food company Nestlé launched a new line of low-sugar supplements.
Before jumping into the news, don’t miss our Interview of the Week. Mexico Health Review talked to Román Rosales, former Minister of Health of Mexico City, about the possible economic and productivity impact of chronic degenerative diseases for the entire population.
Ready for more? Check out what made the headlines over the past week.
- The Inter-American Development Bank forecasts Mexico will need 4.6 million professionals in health and education by 2040. Teachers’, doctors’ and nurses’ income in Latin America and the Caribbean also grew significantly in recent years in comparison to other professionals.
- Jorge Alcocer, Minister of Health, dismisses a potential sanitary alert for measles despite the shortage of vaccines during 2018. Alcocer said the government addressed the issue and supply of vaccines will be restored in a week.
- Danish pharmaceutical Novo Nordisk will invest MX$352 million (US$18.4 million) in clinical research in the next two years in Mexico, a figure that doubles the company’s investment in the country over the past five years.
- UNAM develops wheat-flour tortillas against malnutrition, obesity and diabetes. One of these 25g tortillas provides 68 to 70kcal, while those offered in the market with the same weight provide between 80 and 100kcal.
- Global Data’s report Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027, reveals the global plaque psoriasis market is expected to grow from US$16.2 billion in 2017 to US$24.2 billion in 2027 at a compound annual growth rate of 4.1 percent.
- Nestlé Health Science recently launched low-sugar supplements that can be included in a balanced diet and consumed by glucose-intolerant or diabetic patients under specialist supervision.
Industry Analyst and Journalist at Mexico Business Publishing